Exagen Inc

NASDAQ: XGN    
Share price (4/19/24): $1.37    
Market cap (4/19/24): $23.8 million

Material Contracts Filter

EX-10.1
from 8-K 8 pages ***This Offer Must Be Accepted by December 10, 2023*** Professional Services Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Exagen Inc. Clawback Policy
12/34/56
EX-10.1
from 10-Q 37 pages Material contract
12/34/56
EX-10.1
from 8-K 7 pages Independent Contractor Agreement
12/34/56
EX-10.2
from 8-K 9 pages Severance Agreement
12/34/56
EX-10.1
from 8-K 5 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 20 pages Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan Effective as of April 25, 2022
12/34/56
EX-10.1
from 8-K 20 pages Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan Effective as of April 25, 2022
12/34/56
EX-10.6
from 10-Q 5 pages Exagen Has the Right to Rely on Such Representations and Warranties in Entering Into This Letter Agreement. Prometheus Agrees to Indemnify Exagen Against Any Losses, Damages or Claims Arising Out of a Breach of Any of Prometheus’ Representations and Warranties in This Letter Agreement
12/34/56
EX-10.4
from 10-Q 1 page First Addendum to Standard Industrial/Commercial Multi-Tenant Lease - Net Dated February 27, 2020 by and Between Rgs Properties, as Lessor and Exagen Diagnostics, Inc., as Lessee, for the Premises Located at 1261 Liberty Way, Suite A, California. Lessor and Lessee Mutually Agree to Amend the Lease as Follows: Parties (1.1): Lessee Has Changed Their Name and Shall Be Referred to as Exagen Inc., a Delaware Corporation Paragraph 1.3 (Term): The Lease Term Will Be Extended to the New Expiration Date of April 30, 2027 Paragraph 50 (Rent Schedule): Base Rent Shall Be as Follows: Dates Base Rent February 1, 2026 - April 30, 2027 $14,750.63 Per Month All Other Terms and Conditions of the Existing Lease Shall Remain in Full Force and Effect. This Addendum Shall Automatically Expire if Not Executed by Lessee on or Before Friday October 15, 2021. Agreed and Accepted: Lessor: Lessee: Rgs Properties Exagen Inc., a Delaware Corporation By: /S/ Scott Smith By: /S/ Ron Rocca By: /S/ Greg Smith Ron Rocca Date: 10/19/2021 Title: CEO Date: 10/12/2021
12/34/56
EX-10.3
from 10-Q 1 page Fifth Addendum to Standard Industrial/Commercial Multi-Tenant Lease - Net Dated January 13, 2012 by and Between Rgs Properties, as Lessor and Exagen Diagnostics, Inc., as Lessee, for the Premises Located at 1261 Liberty Way, Suites B & C, California. Lessor and Lessee Mutually Agree to Amend the Lease as Follows: Parties (1.1): Lessee Has Changed Their Name and Shall Here for Be Referred to as Exagen Inc., a Delaware Corporation Paragraph 1.3 (Term): The Lease Term Will Be Extended to the New Expiration Date of April 30, 2027 Paragraph 50 (Rent Schedule): Base Rent Shall Be as Follows: Dates Base Rent February 1, 2026 - April 30, 2027 $20,084.42 Per Month All Other Terms and Conditions of the Existing Lease Shall Remain in Full Force and Effect. This Addendum Shall Automatically Expire Is Not Executed by Lessee on or Before Friday October 15, 2021. Agreed and Accepted: Lessor: Lessee: Rgs Properties Exagen Inc., a Delaware Corporation By: /S/ Scott Smith By: /S/ Ron Rocca By: /S/ Greg Smith Ron Rocca Date: 10/19/2021 Title: CEO Date: 10/12/2021
12/34/56
EX-10.2
from 10-Q 2 pages Second Amendment of Lease
12/34/56
EX-10.1
from 10-Q 98 pages Sublease Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Exagen Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Exagen Inc. if Publicly Disclosed. Amendment #4 to Co-Promotion Agreement
12/34/56
EX-10.46
from 10-K 19 pages Exagen Inc. Executive Change in Control Severance Plan
12/34/56
EX-10.34
from 10-K ~5 pages First Amendment of Lease
12/34/56
EX-10.25
from 10-K 2 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Exagen Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Exagen Inc. if Publicly Disclosed. Amendment #3 to Co-Promotion Agreement
12/34/56
EX-10.5
from 10-K 5 pages Exagen Inc. 2019 Incentive Award Plan Restricted Stock Unit Grant Notice
12/34/56
EX-10.2
from 10-Q 6 pages Amendment #2 to Co-Promotion Agreement
12/34/56
EX-10.1
from 10-Q ~5 pages Amendment #1 to Co-Promotion Agreement
12/34/56